Voluntarily participating in the clinical study, fully understanding and being fully informed of the study and having signed the Informed Consent Form (ICF) <br/ >1. Age 18-80 years (inclusive) at the time of signing ICF. <br/ >2. SARS-CoV-2 positive report â?? rtPCR or Rapid Antigen <br/ >3. Initial COVID-19 symptom onset within 4 days prior to Screening <br/ >4. For female subjects: evidence of post-menopause, or for pre-menopause subjectâ??s negative pre-treatment serum or urine pregnancy test <br/ >5. Eligible subjects of child-bearing age (male or female) must agree to take effective contraceptive measures (including hormonal contraception, barrier methods or abstinence) with his/her partner during the study period and for at least 7 days following the last study treatment <br/ >6. SpO2 â?¥ 93% on room air <br/ >7. Not participating in any other interventional drug clinical studies before completion of the present study. <br/ >

Voluntarily participating in the clinical study, fully understanding and being fully informed of the study and having signed the Informed Consent Form (ICF) <br/ >1. Age 18-80 years (inclusive) at the time of signing ICF. <br/ >2. SARS-CoV-2 positive report â?? rtPCR or Rapid Antigen <br/ >3. Initial COVID-19 symptom onset within 4 days prior to Screening <br/ >4. For female subjects: evidence of post-menopause, or for pre-menopause subjectâ??s negative pre-treatment serum or urine pregnancy test <br/ >5. Eligible subjects of child-bearing age (male or female) must agree to take effective contraceptive measures (including hormonal contraception, barrier methods or abstinence) with his/her partner during the study period and for at least 7 days following the last study treatment <br/ >6. SpO2 â?¥ 93% on room air <br/ >7. Not participating in any other interventional drug clinical studies before completion of the present study. <br/ >

Voluntarily participating in the clinical study, fully understanding and being fully informed of the study and having signed the Informed Consent Form (ICF) <br/ >1. Age 18-80 years (inclusive) at the time of signing ICF. <br/ >2. SARS-CoV-2 positive report â?? rtPCR or Rapid Antigen <br/ >3. Initial COVID-19 symptom onset within 4 days prior to Screening <br/ >4. For female subjects: evidence of post-menopause, or for pre-menopause subjectâ??s negative pre-treatment serum or urine pregnancy test <br/ >5. Eligible subjects of child-bearing age (male or female) must agree to take effective contraceptive measures (including hormonal contraception, barrier methods or abstinence) with his/her partner during the study period and for at least 7 days following the last study treatment <br/ >6. SpO2 â?¥ 93% on room air <br/ >7. Not participating in any other interventional drug clinical studies before completion of the present study. <br/ >

Voluntarily participating in the clinical study, fully understanding and being fully informed of the study and having signed the Informed Consent Form (ICF) <br/ >1. Age 18-80 years (inclusive) at the time of signing ICF. <br/ >2. SARS-CoV-2 positive report â?? rtPCR or Rapid Antigen <br/ >3. Initial COVID-19 symptom onset within 4 days prior to Screening <br/ >4. For female subjects: evidence of post-menopause, or for pre-menopause subjectâ??s negative pre-treatment serum or urine pregnancy test <br/ >5. Eligible subjects of child-bearing age (male or female) must agree to take effective contraceptive measures (including hormonal contraception, barrier methods or abstinence) with his/her partner during the study period and for at least 7 days following the last study treatment <br/ >6. SpO2 â?¥ 93% on room air <br/ >7. Not participating in any other interventional drug clinical studies before completion of the present study. <br/ >